Future Fund LLC Has $1.66 Million Holdings in ADMA Biologics Inc $ADMA

Future Fund LLC raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 88.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,016 shares of the biotechnology company’s stock after acquiring an additional 86,584 shares during the quarter. Future Fund LLC owned approximately 0.08% of ADMA Biologics worth $1,658,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. State Street Corp boosted its holdings in shares of ADMA Biologics by 0.3% during the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after purchasing an additional 35,614 shares during the period. Sachem Head Capital Management LP increased its stake in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after buying an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP lifted its position in ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after buying an additional 1,886,105 shares in the last quarter. Capital Research Global Investors lifted its position in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares in the last quarter. Finally, Nuveen LLC boosted its stake in shares of ADMA Biologics by 3.5% during the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after buying an additional 202,245 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

ADMA stock opened at $8.71 on Friday. The firm has a 50 day moving average of $8.46 and a two-hundred day moving average of $12.28. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of 12.81 and a beta of 0.73. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same quarter last year, the firm earned $0.11 EPS. ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. As a group, equities analysts anticipate that ADMA Biologics Inc will post 0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ADMA. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Mizuho lowered their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday. Raymond James Financial began coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple plaintiff law firms announced or reiterated the August 10, 2026 deadline for investors to seek lead plaintiff status in the ADMA securities class action, keeping the litigation in focus for shareholders. Article Title
• Neutral Sentiment: Additional notices from firms including Faruqi & Faruqi, Kahn Swick & Foti, Robbins LLP, and Rosen Law Firm reinforce that a class action is already underway, suggesting ongoing legal overhang rather than any operational update. Article Title
• Neutral Sentiment: A Yahoo Finance-linked piece and other commentary reference class actions and probes over revenue allegations, indicating the market is still processing the underlying claims against ADMA Biologics. Article Title

Insider Buying and Selling

In related news, Director Jerrold B. Grossman bought 12,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.90% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.